Figure 2From: Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response Effect of patient characteristics/demographics on the efficacy of donepezil 23 mg/d or 10 mg/d measured by LS mean change in SIB score from baseline to Week 24. A. Age. B. Gender. C. Weight.Back to article page